Latest Industry Insights

As the use of generative AI tools expands, and their potential in scientific research is better understood, there are ethical considerations to be made. Dr. Dror Kolodkin-Gal explores some of the issues and potential solutions.

Bio-Rad's Jeremiah McDole explores the benefits of bringing molecular testing in-house and how ddPCR technology can be applied in oncology workflows.

In this interview, James Brayer delves into some of the current obstacles hindering the widespread adoption of genomic medicine and highlights how nanopore-based sequencing can help to address them.

Technology Networks spoke to Dr. Ofer Sharon, CEO of OncoHost, to learn about the challenges in non-small cell lung cancer treatment and how proteomics-based analysis could enable personalized cancer treatments.

This article looks at the technologies currently being developed that can help to identify patients with a higher risk of prostate cancer, ultimately reducing the number of unnecessary biopsies.

Andrew Schulman explores why we need allogeneic therapies, the importance of collaboration to keep the momentum, and challenges and predictions for the future.

With growing sustainability demands, companies are looking for ways to demonstrate their green credentials. We spoke to Dr. Michael Frank to find out what ACT accreditation means for a company and why he thinks schemes like this are so important.

This article discusses how the culture of canine-derived organoid lines can be used to make meaningful observations in the emerging field of comparative oncology, prompting the next revolution in animal and human cancer studies.

HPLC system manufacturers have been striving to improve usability, accessibility and help users improve their experimental outcomes. And what better way to do that than to involve the users themselves in that development process.

We spoke with Bio-Rad’s Justin Barker to discover some of the challenges associated with gene expression analysis in oncology and learn about technology developments in this field.